Eperisone Hydrochloride, a Muscle Relaxant, Is a Potent P2X7 Receptor Antagonist
- Chem Pharm Bull (Tokyo). 2024;72(3):345-348. doi: 10.1248/cpb.c24-00032.
- 1. ASKA Pharmaceutical Co., Ltd., Research Management Department.
- 2. ASKA Pharmaceutical Co., Ltd., Drug Development Department.
Eperisone Hydrochloride was launched in Japan in 1983 and has been used to improve muscle tone and treat spastic paralysis (Originator: Eisai Co., Ltd.). However, its biochemical mechanism of action is unknown. SB Drug Discovery was used to evaluate purinergic P2X (P2X) receptor antagonism using fluorescence. In this study, we discovered that its target protein is the P2X7 Receptor. Also, P2X Receptor subtype selectivity was high. This finding demonstrates the (Eperisone-P2X7-pain linkage), the validity of P2X7 as a drug target, and the possibility of drug repositioning of Eperisone Hydrochloride.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
99.95%, Antispastic Agent, Muscle Relaxant, P2X7 Receptor Antagonisttarget: P2X ReceptorResearch Areas: Neurological Disease
-
99.96%, Antispastic Agent, Muscle Relaxant, P2X7 Receptor AntagonistResearch Areas: Neurological Disease
-
target: P2X ReceptorResearch Areas: Neurological Disease